
Irena Misiewicz-Krzeminska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4409946/publications.pdf

Version: 2024-02-01



#	Article	IF	CITATIONS
1	Deregulation of microRNA expression in the different genetic subtypes of multiple myeloma and correlation with gene expression profiling. Leukemia, 2010, 24, 629-637.	7.2	188
2	Restoration of microRNA-214 expression reduces growth of myeloma cells through positive regulation of P53 and inhibition of DNA replication. Haematologica, 2013, 98, 640-648.	3.5	75
3	Microvesicles from Mesenchymal Stromal Cells Are Involved in HPC-Microenvironment Crosstalk in Myelodysplastic Patients. PLoS ONE, 2016, 11, e0146722.	2.5	70
4	Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma. International Journal of Molecular Sciences, 2016, 17, 2003.	4.1	59
5	Sulforaphane and its analogues inhibit CYP1A1 and CYP1A2 activity induced by benzo[<i>a</i>]pyrene. Journal of Biochemical and Molecular Toxicology, 2009, 23, 18-28.	3.0	41
6	A comparison of the concentration–effect relationships of PAHs on CYP1A induction in HepG2 and Mcf7 cells. Archives of Toxicology, 2007, 81, 183-200.	4.2	31
7	The effect of isothiocyanates on CYP1A1 and CYP1A2 activities induced by polycyclic aromatic hydrocarbons in Mcf7 cells. Toxicology in Vitro, 2009, 23, 763-771.	2.4	31
8	Upregulation of Dicer is more frequent in monoclonal gammopathies of undetermined significance than in multiple myeloma patients and is associated with longer survival in symptomatic myeloma patients. Haematologica, 2011, 96, 468-471.	3.5	29
9	Factors Regulating microRNA Expression and Function in Multiple Myeloma. Non-coding RNA, 2019, 5, 9.	2.6	29
10	Amiloride, An Old Diuretic Drug, Is a Potential Therapeutic Agent for Multiple Myeloma. Clinical Cancer Research, 2017, 23, 6602-6615.	7.0	25
11	Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. Journal of Hematology and Oncology, 2017, 10, 127.	17.0	25
12	DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma. Journal of Hematology and Oncology, 2017, 10, 92.	17.0	23
13	Insights into epigenetic regulation of microRNA-155 expression in multiple myeloma. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 353-366.	1.9	22
14	Post-transcriptional Modifications Contribute to the Upregulation of Cyclin D2 in Multiple Myeloma. Clinical Cancer Research, 2016, 22, 207-217.	7.0	21
15	Selenitetriglicerydes affect CYP1A1 and QR activity by involvement of reactive oxygen species and Nrf2 transcription factor. Pharmacological Reports, 2010, 62, 352-361.	3.3	19
16	The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. Haematologica, 2017, 102, 2113-2124.	3.5	19
17	Mitochondrial localization of P2Y1, P2Y2 and P2Y12 receptors in rat astrocytes and glioma C6 cells. Brain Research Bulletin, 2007, 71, 587-592.	3.0	18
18	Decytabine enhances cytotoxicity induced by oxaliplatin and 5-fluorouracil in the colorectal cancer cell line Colo-205. Cancer Cell International, 2009, 9, 10.	4.1	17

#	Article	IF	CITATIONS
19	MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. BMC Cancer, 2015, 15, 238.	2.6	16
20	Transcriptome analysis reveals significant differences between primary plasma cell leukemia and multiple myeloma even when sharing a similar genetic background. Blood Cancer Journal, 2019, 9, 90.	6.2	16
21	Quantitative expression of Ikaros, IRF4, and PSMD10 proteins predicts survival in VRD-treated patients with multiple myeloma. Blood Advances, 2020, 4, 6023-6033.	5.2	15
22	Expression of p53 protein isoforms predicts survival in patients with multiple myeloma. American Journal of Hematology, 2022, , .	4.1	13
23	A novel nano-immunoassay method for quantification of proteins from CD138-purified myeloma cells: biological and clinical utility. Haematologica, 2018, 103, 880-889.	3.5	12
24	Does molecular docking reveal alternative chemopreventive mechanism of activation of oxidoreductase by sulforaphane isothiocyanates?. Journal of Molecular Modeling, 2010, 16, 1205-1212.	1.8	9
25	A novel capillary nano-immunoassay for assessing androgen receptor splice variant 7 in plasma. Correlation with CD133 antigen expression in circulating tumor cells. A pilot study in prostate cancer patients. Clinical and Translational Oncology, 2017, 19, 1350-1357.	2.4	6
26	Isothiocyanate–drug interactions in the human adenocarcinoma cell line Caco-2. Molecular and Cellular Biochemistry, 2012, 367, 19-29.	3.1	4
27	The CRBN, CUL4A and DDB1 Expression Predicts the Response to Immunomodulatory Drugs and Survival of Multiple Myeloma Patients. Journal of Clinical Medicine, 2021, 10, 2683.	2.4	4
28	Influence of protoporphyrin IX amino acid substituents on affinity to human breast adenocarcinoma MCF-7 cells. Biotechnic and Histochemistry, 2009, 84, 17-23.	1.3	3
29	Effect of Graphene Family Materials on Multiple Myeloma and Non-Hodgkin's Lymphoma Cell Lines. Materials, 2020, 13, 3420.	2.9	3
30	Capillary Nano-immunoassay for Quantification of Proteins from CD138-purified Myeloma Cells. Bio-protocol, 2019, 9, e3267.	0.4	3
31	Tracking Clonal Evolution of Multiple Myeloma Using Targeted Next-Generation DNA Sequencing. Biomedicines, 2022, 10, 1674.	3.2	3
32	Post-Transcriptional Modifications Explain the Overexpression of CCND2 in Multiple Myeloma. Blood, 2014, 124, 2001-2001.	1.4	2
33	Filanesib Primarily Initiates the Apoptotic Program By Activating Bax through a Calpain-Dependent Mechanism. Blood, 2015, 126, 5353-5353.	1.4	1
34	Inhibition of cell cycle and induction of apoptosis by 2-oxoheksyl isothiocyanate and alyssin in cell lines carrying various inheritedBRCA1 mutations. Drug Development Research, 2005, 65, 84-92.	2.9	0
35	Quantification of proteins from CD138-purified myeloma cells using the capillary nano-immunoassay technology is a better predictor of survival than the corresponding gene expression value. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e4-e5.	0.4	0
36	PD71-08 ANDROGEN RECEPTOR SPLICE VARIANT 7 (AR-V7) IN PATIENTS WITH LOCAL ADVANCED, METASTATIC AND CRPCM: A NOVEL CAPILLARY NANO-INMUNOASSAY TECHNIQUE. Journal of Urology, 2017, 197, .	0.4	0

#	Article	IF	CITATIONS
37	Prognostic Implications of PIM-2 Expression in Samples from Patients with Chronic Lymphocytic Leukemia and Impact in the Sensitivity to the Pan-PIM Kinase Inhibitor PIM447. Blood, 2015, 126, 2923-2923.	1.4	0
38	Determination of AR-V7 in plasma in patients with metastatic prostate cancer using capillary	1.6	0

Determination of AR-V7 in plasma in patients with metastatic prostate cancer using capillary Nano-immunoassay.. Journal of Clinical Oncology, 2019, 37, e16574-e16574. 38